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Cats were vaccinated with fixed autologous feline
immunodeficiency virus (FIV)-infected cells in order
to present viral proteins to the immune system of
individual cats in an MHC-matched fashion. Upon
vaccination, a humoral response against Gag was
induced. Furthermore, virus-neutralizing anti-
bodies were detected in a Crandell feline kidney
cell-based neutralization assay, but not in a neutral-
ization assay based on primary peripheral blood
mononuclear cells. Despite the induction of these
FIV-specific responses, vaccinated cats were not
protected. Instead, accelerated virus replication
was found, an observation similar to what previous
experiments using other vaccine candidates have
shown. Here, the results of the present study are
discussed in the light of enhancement of lentivirus
infections as a complicating factor in lentivirus
vaccine development.
Feline immunodeficiency virus (FIV) infection of the cat
serves as a suitable model to study the pathogenesis of human
immunodeficiency virus (HIV) infection and has been used to
evaluate lentivirus vaccine development strategies (Willett et
al., 1997). Several of these have been based on the use of
envelope glycoproteins of FIV. Envelope-based lentivirus
vaccines, however, may induce enhanced rather than decreased
susceptibility to challenge infection or disease (Hosie et al.,
1992 ; Lombardi et al., 1994 ; Wang et al., 1994 ; Siebelink et al.,
1995 ; Montelaro et al., 1996 ; Richardson et al., 1997). We have
previously shown that cats vaccinated with recombinant
envelope protein-based candidate vaccines exhibited an accel-
erated viraemia upon challenge infection, which was most
likely mediated by virus-specific antibodies (Siebelink et al.,
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1995). Antibody-mediated enhancement of HIV-1 in vitro
proved to be related to the syncytium-inducing phenotype of
the virus, which is directly related to the envelope glycoprotein
structure (Allan et al., 1990 ; Schutten et al., 1995 ; Kostrikis et
al., 1996). In the present study, we have vaccinated cats with
fixed autologous FIV-infected or uninfected peripheral blood
mononuclear cells (PBMC) and challenged with the hom-
ologous molecular clone FIV-19k1. This approach was chosen
to take advantage of the induction of cell-mediated immunity,
since antigen presentation would take place in an MHC-
matched fashion in each individual cat. We and others have
recently shown that cellular immune responses against lenti-
viral proteins are of major importance in controlling lentivirus
replication and disease (Flynn et al., 1995, 1996 ; Hosie et al.,
1996 ; van Baalen et al., 1997 ; Ogg et al., 1998). Since we
showed that paraformaldehyde is a relatively mild fixative for
lentivirus membrane glycoproteins (Hulskotte et al., 1997), we
speculate that the envelope protein in this candidate vaccine
was indeed presented in a way that closely resembles the
native form, which may not always be the case with subunit
vaccines. The HIV-1 envelope proteins of primary isolates are
organized in oligomeric structures, which may be necessary for
the induction of effective neutralizing antibodies (Poignard et
al., 1996). Also, when using this strategy we could exclude any
Fig. 1. Kinetics of the antibody titre developed against the Gag protein.
Cats no. 2, 9 and 12 were vaccinated with fixed autologous FIV-19k1-
infected PBMC. Cats no. 7 and 13 were vaccinated with fixed autologous
uninfected PBMC. Small arrows, time-points of vaccination ; large arrow,
time-point of challenge.
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Fig. 2. Virus-neutralizing antibody titres
of the individual cats at different weeks
post-vaccination as measured in the CrFK
virus-neutralization assay. Cats no. 2, 9
and 12 were vaccinated with fixed
autologous FIV-19k1-infected PBMC.
Cats no. 7 and 13 were vaccinated with
fixed autologous uninfected PBMC.
beneficial role of antibodies against cellular proteins in
protection against infection as has been described in simian
immunodeficiency virus vaccine studies (Stott, 1991 ; Oster-
haus et al., 1992).
PBMC of five 6-month-old cats (nos 2, 7, 9, 12, 13) were
obtained and cultured as described previously (Siebelink et al.,
1995) and were infected after 7 days with 1000 CID
&!
of
molecular clone FIV-19k1 (Siebelink et al., 1992). In parallel,
cultures with uninfected cells from each cat were maintained.
Virus production was measured in an antigen ELISA (Siebelink
et al., 1990). As soon as FIV antigen was detected in the culture
supernatant, the percentage of infected cells was determined
by an immunofluorescence assay, using serum of an ex-
perimentally FIV-infected specific-pathogen-free (SPF) cat. The
number of infected PBMC for cats no. 2, 9 and 12 was
approximately 5%, whereas this was found to be approxi-
mately 1% for cats no. 7 and 13. This variability in the in vitro
rate is common in our experience when infection is allowed to
progress for a limited period of time. This observation is
probably due to minor differences in culture conditions.
Subsequently, infected as well as uninfected cells from all cats
were inactivated with 1–25% paraformaldehyde as previously
described (Yamamoto et al., 1991). Complete inactivation of
the vaccines was confirmed in vitro by co-cultivation of the
vaccines with autologous cells and in vivo by attempting to
reisolate FIV from the PBMC of cats following two inocu-
lations with fixed autologous FIV-infected cells. Neither
method led to antigen production as measured in an antigen
ELISA (Siebelink et al., 1990). Three cats (nos 2, 9 and 12) were
vaccinated with fixed autologous FIV-19k1-infected cells. The
two other cats (nos 7 and 13) served as controls and received
fixed autologous non-infected cells. The cats were vaccinated
six times at weeks 0, 2, 4, 6, 8 and 16 intravenously and
subcutaneously, each time with 5‹10’ cells. Challenge
infection was performed intramuscularly with 10 CID
&!
of
molecular clone FIV-19k1 at week 18. Blood samples were
collected at weekly intervals during the first 4 weeks and at
week 6 and 10 post-challenge. We determined the devel-
opment of Gag-specific antibodies in plasma by ELISA as
described before (Siebelink et al., 1995). All cats vaccinated
with fixed autologous FIV-infected cells developed a Gag-
specific antibody response after three vaccinations (Fig. 1). On
the day of challenge the titres of the three vaccinated cats
varied from 400 to 1600, while the two controls remained
sero-negative. Antibody responses measured against two Env
peptides (SU and TM) were also determined as previously
described (Siebelink et al., 1995) and were negative for all cats
except at one time-point for cat no. 12, which showed an
ELISA titre of 200 after three vaccinations (data not shown).
Virus-neutralizing antibody titres were determined using two
systems : the first is based on inhibition of infection of Crandell
feline kidney (CrFK) cells with CrFK cell-adapted virus FIV-
AM6c (Siebelink et al., 1995), and the second is based on
inhibition of infection of primary PBMC with molecular clone
FIV-19k1 (Siebelink et al., 1993). In the assay based on CrFK
cells, virus-neutralizing antibodies could be detected in sera of
the cats vaccinated with fixed autologous FIV-infected cells
from the second vaccination onward, reaching titres of
640–1280 on the day of challenge (Fig. 2). FIV-neutralizing
antibodies could not be demonstrated in the two control cats
before challenge. No virus-neutralizing activity could be
detected in the serum of any cat on the day of challenge in the
assay based on primary PBMC. Gag-specific antibodies became
detectable in the control cats at 10 weeks post-challenge,
reaching a titre of 1600 in both cats. In the vaccinated cats, an
anamnestic response against Gag was evident from 2 weeks
post-challenge onward (Fig. 1). These titres increased sub-
stantially in the following weeks, ranging from 800 to 13000,
except for cat no. 12, which showed a lower titre rise upon
challenge. Cell-associated virus loads were determined with an
infectious centre test as previously described (Siebelink et al.,
1995). In the cats vaccinated with fixed autologous FIV-
infected cells, 10–36 and 30–80 FIV-infected cells per 10’
PBMC were demonstrated 2 and 3 weeks post-challenge
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Fig. 3. The upper part of the figure shows the numbers of FIV-infected cells per 106 PBMC at different time-points post-
challenge. Serially diluted PBMC samples (103, 3‹103 and 104 cells) from the vaccinated and challenged cats were co-
cultivated with 105 ConA- and IL-2-stimulated PBMC from an SPF cat in ten duplicate wells. After 3 weeks the culture
supernatants were tested for the presence of FIV antigen by ELISA. The numbers of infected cells in the PBMC were calculated
by assuming that one infected cell would give rise to antigen production. The lower part represents the presence of proviral
DNA in PBMC of the cats at different time-points post-challenge, as determined with a nested gag PCR. Primer pair FIVDP1 (5«
GGCCCTCCACAGGCATATCC) and FIVDP2 (5« GCATTTTATATCCTGGTGAGCC) was used for the first reaction and primer pair
FIVDP3 (5« GGCAAGAGAAGGACTAGGAGG) and FIVDP4 (5« GCACAGCTCGAGGAGACTTAGC) was used for the nested
reaction. fi, Negative in PCR; ›, positive in PCR; NT, not tested. Cats no. 2, 9 and 12 were vaccinated with fixed autologous
FIV-19k1-infected PBMC. Cats no. 7 and 13 were vaccinated with fixed autologous uninfected PBMC.
respectively, whereas in the control cats no FIV-infected cells
could be detected (Fig. 3). From 4 weeks post-challenge
onward FIV-infected cells could also be determined in the two
control cats. From 6 weeks post-challenge onward no differ-
ences in virus load between the two groups could be
demonstrated. These observations were confirmed using a
nested PCR based on the gag gene of FIV (Fig. 3). The cats
vaccinated with fixed autologous FIV-19k1-infected PBMC
contained proviral DNA in PBMC from 2weeks post-challenge
onward, whereas proviral DNA in the control cats could be
shown from 4 weeks post-challenge onward. To determine
whether antibodies were the cause of the observed enhance-
ment, we purified immunoglobulins from plasma of both
groups of cats, collected on the day of challenge, by means of
protein A affinity chromatography. Naı$ve kittens were inocu-
lated with 10 ml of whole plasma or an equivalent amount of
purified immunoglobulins and subsequently challenged intra-
muscularly with 10 CID
&!
of molecular clone FIV-19k1. Blood
samples were taken at the same time-points as described for the
vaccinated cats. The virus loads of the cats were monitored
using the infectious centre test and PCR. No differences in the
kinetics of FIV infection and virus loads were observed
between the four groups of cats.
Although we did not show the induction of virus-specific
MHC class I-restricted CTL, we may expect that in these
experiments, presentation of the envelope protein of FIV in its
natural form and presentation of antigenic peptides derived
thereof by matched MHC molecules did indeed result in the
induction of these CTL. Consequently, if we assume that such
CTL contribute to protective immunity we would have
expected that this type of immunization would have led to
protective immunity against a homologous challenge infection
with molecularly cloned FIV. Instead, an accelerated viraemia
was observed after challenge infection. Enhancement of
challenge infection was observed in a previous study, after
vaccination of cats with FIV subunit vaccines (Siebelink et al.,
1995) based on recombinant envelope protein incorporated
into immune-stimulating complexes (iscom) (Rimmelzwaan et
al., 1994). Vaccine-induced envelope protein-specific antibody
titres, as measured in the virus-neutralization assay based on
CrFK cells, were similar in both studies. However, antibody
titres directed against two peptides derived from the envelope
protein were much lower in the cats vaccinated with fixed
autologous FIV-infected cells than in the cats vaccinated with
FIV Env iscom, which may explain the failure to transfer the
phenomenon of accelerated viraemia to naı$ve kittens by means
of plasma and purified immunoglobulins from this plasma in
the present study. Besides the role of complement- and Fc-
receptors in antibody-mediated enhancement, it has recently
been described that the virus phenotype may also be involved
(Schutten et al., 1995). This was shown with monoclonal
antibodies and virtually identical virus isolates derived from
one patient. Some monoclonal antibodies neutralized sync-
ytium-inducing viruses, whereas the replication of a non-
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syncytium-inducing variant proved to be enhanced. A similar
mechanism may play a role in the vaccination studies
performed in the equine infectious anaemia virus model, where
protection was found against homologous challenge after
vaccination with recombinant envelope protein. In contrast,
enhancement of infection was found in animals challenged
with a heterologous virus (Montelaro et al., 1996). This
principle may also have played a role in our previous study, in
which cats were vaccinated with recombinant envelope protein
incorporated into iscom and where a biological FIV isolate was
used for the challenge infection. This isolate contains a swarm
of viruses, including the highly homologous molecular clones
FIV-19k1 and FIV-19k32 (Siebelink et al., 1992). It is of interest
to note that FIV-19k1 is neutralized by its homologous serum,
while FIV-19k32 was enhanced by the same antiserum (K.
Siebelink, personal communication), indicating that there is a
delicate balance between enhancement and neutralization. In
the present study, however, it is unlikely that this mechanism
of heterotypic enhancement of infection played a role, since a
homologous molecular clone was used for challenge. Recently
immune activation has been suggested as a possible mechanism
for enhanced replication of FIV in a vaccination study
(Richardson et al., 1997). Furthermore, immune activation,
including the activation of T-cells, seems to play a role in HIV-
1-infected individuals who are vaccinated against opportunistic
pathogens and who show a rise in HIV-1 virus load in plasma
as a consequence of this (Ho, 1992 ; Staprans et al., 1995 ;
Brichacek et al., 1996 ; Goletti et al., 1996). It may be speculated
that in the present study, in which a challenge infection was
carried out only 2 weeks after the last booster vaccination,
immune activation may also have played a role. To evaluate
this possibility, we determined the induction of IFN-c and IL-
4 in PBMC after vaccination and challenge in both groups of
cats. No differences in cytokine expression were observed,
suggesting that immune activation did not play a role in the
enhanced virus replication. However, cytokines other than
IFN-c and IL-4 may have played a role in the observed
enhancement. Recently, it has been described that IL-10
upregulates expression of CCR-5 (Sozzani et al., 1998), the
chemokine receptor involved in infection of macrophage-
tropic variants of HIV-1 (Choe et al., 1996). This resulted in an
enhanced in vitro infection of peripheral blood lymphocytes
with HIV-1. Similar mechanisms, affecting primary or sec-
ondary receptors used by FIV, may be involved in the outcome
of the study described here. The results obtained in the present
experiments and in other studies referred to above show that
enhancement of lentivirus infections can be a major problem in
vaccine development. Several mechanisms can form the basis
of this and it is important that the contribution of these
mechanisms are addressed.
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